Acadia Pharmaceuticals
ACAD
203 hedge funds and large institutions have $3.34B invested in Acadia Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 86 increasing their positions, 64 reducing their positions, and 35 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 64
0.32% less ownership
Funds ownership: 98.47% → 98.15% (-0.32%)
7% less funds holding
Funds holding: 219 → 203 (-16)
19% less capital invested
Capital invested by funds: $4.11B → $3.34B (-$770M)
27% less call options, than puts
Call options by funds: $29.6M | Put options by funds: $40.6M
40% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 35
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$109M |
| 2 |
Goldman Sachs
New York
|
+$23.4M |
| 3 |
Millennium Management
New York
|
+$16.4M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$15.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$40.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.7M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$30.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.7M |
| 5 |
JP
Jana Partners
New York
|
-$14.5M |
ACAD Hedge Fund Activity: Q2 2017 in Review
203 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2017, worth a combined $3.34B — down 19% from $4.11B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ACAD and 21 opened new positions — a net loss of 14 holders — while 64 trimmed existing stakes and 86 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $109M. The largest seller was OrbiMed, exiting entirely with an estimated $40.2M sold.
- 203 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2017, down from 219 in Q1 2017.
- Funds reported $3.34B of Acadia Pharmaceuticals stock for Q2 2017, down 19% quarter-over-quarter.
- 21 funds opened new Acadia Pharmaceuticals positions in Q2 2017 and 35 closed out, a net change of -14 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $109M added.
- The largest Acadia Pharmaceuticals seller in Q2 2017 was OrbiMed, an estimated $40.2M sold.
Based on aggregated 13F filings for Q2 2017.